Accrued and Other Liabilities

9 Months Ended

Sep. 30, 2023

(9) Accrued and Other Liabilities

Short-Term Accrued Liabilities

Accrued liabilities at September 30, 2023 and December 31, 2022 are summarized as follows:


(in thousands)	September 30, 2023		December 31, 2022
Compensation and benefits	$	15,492	$	19,814
Accrued taxes	9,633		10,694

Legal contingencies	4,850		9,948
Product warranty liability	2,409		3,677



Other accrued liabilities	11,191		11,438
Total	$	43,575	$	55,571

Changes in the product warranty obligation for the nine months ended September 30, 2023 and 2022 are summarized below:


(in thousands)	Beginning Balance		Settlements Made		Accruals for Warranties Issued		Ending Balance
September 30, 2023	$	3,677	$	(2,983)	$	1,715	$	2,409
September 30, 2022	$	3,585	$	(5,266)	$	5,257	$	3,576

Other Long-Term Liabilities

Other liabilities at September 30, 2023 and December 31, 2022 are summarized as follows:


(in thousands)	September 30, 2023		December 31, 2022
Long-term employee indemnity	$	4,634	$	4,817
Long-term tax liability	5,568		5,711
Defined benefit pension obligation	4,963		5,050
Long-term deferred revenue	1,858		4,974
Earnout liability	—		17,244
Legal contingencies	2,916		6,096
Other long-term liabilities	428		289
Total	$	20,367	$	44,181

The reduction in the earnout liability balance is the result of the reversal of all previously recognized expense attributable to a potential post-acquisition milestone-based payment related to the Company's 2021 acquisition of Volumetric Biotechnologies, Inc. ("Volumetric"). During the three months ended September 30, 2023, the Company reversed the accrued compensation expense related to the potential earnout payment as the related milestone is no longer deemed probable of being achieved. Refer to Note 12 for additional details regarding the earnout arrangement and the financial impact of this milestone-based payment no longer being deemed probable of being paid.